Pharma had always supported some investigator initiated trials (where the Md still owned the data and ran the study) but these, at their worst, were a goodie to give an MD more than a hope that a meaningful result would emerge. Their 500k cap was fine when you could find common cancers everywhere
But then the molecular revolution happened and there were no common cancers. All feasible studies had to be multisite. And that meant much bigger budgets for the coordination.
ATOMIC and its sister consortia in gi, breast and gu cancers filled that gap. A full service CRO to coordinate, to negotiate budget and to allow the members to craft the research and mentor each other was and is the heart of each.
In this paper one of our MVPs David Gerber from UTSW pulled all ten years of our IIT data. 25percent get funded, median budget 2 million (up to nearly 8 million), tight timelines, guidance for what works and a generation of grown opinion leaders 💚 Baboom
Comments